GNE-9605
GNE-9605 Basic information
- Product Name:
- GNE-9605
- Synonyms:
-
- GNE-9605
- N2-(5-chloro-1-(3-fluoro-1-(oxetan-3-yl)piperidin-4-yl)-1H-pyrazol-4-yl)-N4-methyl-5-(trifluoromethyl)pyrimidine-2,4-diamine
- rel-N2-[5-Chloro-1-[(3R,4R)-3-fluoro-1-(3-oxetanyl)-4-piperidinyl]-1H-pyrazol-4-yl]-N4-methyl-5-(trifluoromethyl)-2,4-pyrimidinediamine
- Diazepam-d8 (exempt preparation)
- CS-1831
- GNE-9605;GNE9605;GNE 9605
- 2,4-Pyrimidinediamine, N2-[5-chloro-1-[(3R,4R)-3-fluoro-1-(3-oxetanyl)-4-piperidinyl]-1H-pyrazol-4-yl]-N4-methyl-5-(trifluoromethyl)-, rel-
- GNE-9605 USP/EP/BP
- CAS:
- 1536200-31-3
- MF:
- C17H20ClF4N7O
- MW:
- 449.83
- Product Categories:
-
- Inhibitors
- Mol File:
- 1536200-31-3.mol
GNE-9605 Chemical Properties
- Boiling point:
- 587.9±60.0 °C(Predicted)
- Density
- 1.67±0.1 g/cm3(Predicted)
- storage temp.
- Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
- solubility
- ≥22.5 mg/mL in DMSO
- form
- solid
- pka
- 5.04±0.60(Predicted)
- color
- White to off-white
GNE-9605 Usage And Synthesis
Description
GNE-9065 is an orally bioavailable and potent inhibitor of leucine-rich repeat kinase 2 (LRRK2; IC50 = 18.7 nM). It is selective for LRRK2 over 178 kinases, inhibiting only TAK1-TAB1 >50% at a concentration of 0.1 μM. GNE-9065 (10 and 50 mg/kg) inhibits LRRK2 Ser1292 autophosphorylation in BAC transgenic mice expressing human LRRK2 protein with the G2019S mutation found in families with autosomal Parkinson’s disease.
Uses
GNE-9605 is a potent, orally active, selective Leucine-rich repeat kinase 2 (LRRK2) inhibitor with an IC50 value of 18.7 nM. GNE-9605 inhibits LRRK2 Ser1292 autophosphorylation. GNE-9605 can be used in research of Parkinson's disease (PD) [1].
in vivo
GNE-9605 (10 and 50 mg/kg; i.p.; once) inhibits LRRK2 Ser1292 autophosphorylation in BAC transgenic mice expressing human LRRK2 protein[1].
GNE-9605 (1 mg/kg, p.o.; 0.5 mg/kg, i.v.; once) displays LRRK2 Ki in the biochemical assay of 2 nM as well as a cellular IC50 of 19 nM. GNE-9605 has a total plasma clearance with excellent oral bioavailability[1].
| Animal Model: | BAC transgenic mice expressing human LRRK2 protein[1]. |
| Dosage: | 10 and 50 mg/kg |
| Administration: | Intraperitoneal injection; once |
| Result: | Inhibited LRRK2 Ser1292 autophosphorylation in a dose-dependent manner. |
| Animal Model: | BAC transgenic mice expressing human LRRK2 protein[1]. |
| Dosage: | 1 mg/kg, p.o.; 0.5 mg/kg, i.v. |
| Administration: | Oral administration and intravenous injection; once |
| Result: | Demonstrated a total plasma clearance of 26 mL min-1 kg-1 with excellent oral bioavailability (90%). |
References
[1]. estrada aa, chan bk, baker-glenn c, et al. discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (lrrk2) small molecule inhibitors. j med chem, 2014, 57(3): 921-936.
GNE-9605Supplier
- Tel
- 15261860116
- sales@elsa-biotech.com
- Tel
- sales@boylechem.com
- Tel
- 021-58950125
- info@chemexpress.com
- Tel
- 400-6206333 1316706386
- anhua.mao@aladdin-e.com
- Tel
- +1 (866) 930-6790
- info@adooq.com